From Seekingalpha · Equity Eagle · · 40s
Glaukos Stock: Second J-Code Rewrites Risk Math
Glaukos' second J-code drug launch reshapes risk math for investors.
In brief
Glaukos' second J-code drug launch reshapes risk math for investors. Glaukos' iDose TR and Epioxa drugs drive 50% YoY sales growth with Medicare coverage risks and strong margins. Originally reported by Seekingalpha.
Glaukos Transition
Glaukos shifts from single-product reimbursement to diversified ophthalmic pharmaceutical platform with two J-coded drugs.
Q2 Sales Growth
Q2 net sales grew 50% YoY to $185.6M driven by iDose TR and Epioxa launch with 85% non-GAAP gross margin.
2026 Sales Guidance
Management raised 2026 net sales guidance to $680, 700M with iDose TR sales expected at $275, 280M.
The one thing
Glaukos' iDose TR and Epioxa drugs drive 50% YoY sales growth with Medicare coverage risks and strong margins.
